Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1Colorectal Neoplasms 1

Interventions

pembrolizumab 44Carboplatin 40Cisplatin 36Paclitaxel 29Nivolumab 24Pemetrexed 24Gemcitabine 23Dexamethasone 21Rituximab 18Ipilimumab 16Cyclophosphamide 15Capecitabine 14Fluorouracil 14Docetaxel 13atezolizumab 13Lenalidomide 12Trastuzumab 12trastuzumab deruxtecan 12Cytarabine 11daratumumab 11durvalumab 11130-nm albumin-bound paclitaxel 10Bevacizumab 10Bortezomib 10Prednisone 10olaparib 10Doxorubicin 9Crizotinib 8Oxaliplatin 8venetoclax 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × IFL protocol × Clear all
NCT02563002 2024-10-03

KEYNOTE-177

Merck Sharp & Dohme LLC

Phase 3 Completed
307 enrolled 16 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡